{"cursor":"24413","size":15,"audio":[],"currentlang":"en","article":"{{drugbox\n| Verifiedfields = changed verifiedrevid = 458271995 image =\n| Infliximab_structure2.jpg\n\n\n| type = mab mab_type = mab source = xi/o target = TNF\n\n\n| tradename = Remicade Drugs.com = pregnancy_category = B legal_US = Rx-only\n| legal_status = routes_of_administration = IV\n\n\n| bioavailability = 92% (IV, if 8% left in the syringe) protein_bound =\n| metabolism = reticuloendothelial system elimination_half-life = 9.5 days\n\n\n| ChemSpiderID_Ref = ChemSpiderID = NA CAS_number_Ref = CAS_number = 170277-31-3\n| ATC_prefix = L04 ATC_suffix = AB02 ATC_supplemental = PubChem = DrugBank_Ref =\n| DrugBank = DB00065 UNII_Ref = UNII = B72HH48FLU KEGG_Ref = KEGG = D02598\n| ChEMBL_Ref = ChEMBL = 1201581\n\n\n| C=6428 | H=9912 | N=1694 | O=1987 | S=46 molecular_weight = 144190.3 g/mol\n}}\n\n\n'Infliximab' (INN; trade name 'Remicade') is a monoclonal antibody against\ntumour necrosis factor alpha (TNF-Î±) used to treat autoimmune diseases. Remicade\nis marketed by Janssen Biotech, Inc. (formerly Centocor Biotech, Inc.) in the\nUSA, Mitsubishi Tanabe Pharma in Japan, Xian Janssen in China, and Schering-\nPlough (now part of Merck & Co) elsewhere.\n{{cite press release\n| title = Remicade Becomes First Anti-TNF Biologic Therapy to Treat One Million\n| Patients Worldwide url = http://www.jnj.com/connect/NewsArchive/all-news-\n| archive/20071106_141812 publisher = Johnson & Johnson date = November 6, 2007\n| accessdate = 2009-11-14\n}} In 2013, two biosimilars were submitted for approval in Europe, by\nHospira and Celltrion Healthcare .{{cite news |title=Billion-dollar biotech drug may soon have\nbiosimilar competition |first=John |last=George |url=http://www.bizjournals.com/philadelphia/news/2013/06/28/biliion-dollar-\nbiotech-drug-may-soon.html |work=Philadelphia Business Journal |date=June 28,\n2013 |accessdate=June 27, 2013 }}\n\nInfliximab was approved by the U.S. Food and Drug Administration (FDA) for the\ntreatment of psoriasis, Crohn's disease, ankylosing spondylitis, psoriatic\narthritis, rheumatoid arthritis, and ulcerative colitis. Infliximab won its\ninitial approval by the FDA for the treatment of Crohn's disease in August\n1998. {{cite web\n| url = http://www.fda.gov/Drugs/DevelopmentApprovalProcess/HowDrugsareDevelop-\n| edandApproved/ApprovalApplications/TherapeuticBiologicApplications/ucm093327-\n| .htm title = Infliximab Product Approval Information - Licensing Action work\n| = Drugs@FDA publisher = U.S. Food and Drug Administration (FDA) accessdate =\n| 2009-11-14\n}}\n\nInfliximab works by binding to TNF-Î±. TNF-Î± is a chemical messenger (cytokine)\nand a key part of the autoimmune reaction. In rheumatoid arthritis, infliximab\nseems to work by preventing TNF-Î± from binding to its receptor in the cell.\n\nInfliximab is an artificial antibody. It was originally developed in mice as a\nmouse antibody. Because humans have immune reactions to mouse proteins, the\nmouse common domains were replaced with similar human antibody domains. Because\nthe antibodies were produced from one cell grown into a clone of identical\ncells, it is called a monoclonal antibody. Furthermore, as a combination of\nmouse and human antibody amino acid sequences, it is called a chimeric\nmonoclonal antibody.\n\nInfliximab was developed by Junming Le and Jan Vilcek at New York University\nSchool of Medicine and developed by Centocor, (now Janssen Biotech, Inc.)\n{{cite journal\n| author = Knight DM title = Construction and initial characterization of a mouse-\n| human chimeric anti-TNF antibody journal = Mol. Immunol. volume = 30 issue =\n| 16 pages = 1443â53 year = 1993 month = November doi = 10.1016/0161-5890(93)90106-\n| L pmid = 8232330 author-separator = , author2 = Trinh H author3 = Le J display-\n| authors = 3 last4 = Siegel first4 = Scott last5 = Shealy first5 = David last6\n| = McDonough first6 = Margaret last7 = Scallon first7 = Bernard last8 = Moore\n| first8 = Maria Arevalo last9 = Vilcek first9 = Jan\n}}\n\nIn the United States, Infliximab can cost $19,000 to $22,000 a year per patient\nwholesale, according to Centocor. [http://www.sfgate.com/cgi-\nbin/article.cgi?f=/c/a/2007/05/08/BUGHAPMN021.DTL \"Priced out of pain relief;\nInsurers balk at high costs of promising new treatments\"], Victoria Colliver,\n[[San Francisco Chronicle]], May 8, 2007\n\nOther monoclonal antibodies targeting TNF-Î± are golimumab (Simponi), adalimumab\n(Humira), and certolizumab pegol (Cimzia). Etanercept also binds and inhibits\nthe action of TNF-Î±, but is not a monoclonal antibody (it is instead a fusion of\nTNF-receptor and an antibody constant region).\n\nInfliximab is administered by intravenous infusion, typically at six- to eight-\nweek intervals, at a clinic or hospital. It cannot be administered orally\nbecause the digestive system would destroy the drug.\n","linknr":738,"url":"Infliximab","recorded":1374764722,"links":["/w/index.php?title=Infliximab&action=edit","/w/index.php?title=Infliximab&action=edit","//bits.wikimedia.org/favicon/wikipedia.ico","/w/opensearch_desc.php","//en.wikipedia.org/w/api.php?action=rsd","//creativecommons.org/licenses/by-sa/3.0/","/w/index.php?title=Special:RecentChanges&feed=atom","//bits.wikimedia.org/en.wikipedia.org/load.php?debug=false&lang=en&modules=ext.gadget.DRN-wizard%2CReferenceTooltips%2Ccharinsert%2Cteahouse%7Cext.rtlcite%2Cwikihiero%7Cext.uls.nojs%7Cmediawiki.legacy.commonPrint%2Cshared%7Cmw.PopUpMediaTransform%7Cskins.vector&only=styles&skin=vector&*","//bits.wikimedia.org/en.wikipedia.org/load.php?debug=false&lang=en&modules=site&only=styles&skin=vector&*","//bits.wikimedia.org/en.wikipedia.org/load.php?debug=false&lang=en&modules=startup&only=scripts&skin=vector&*","//bits.wikimedia.org/geoiplookup","//meta.wikimedia.org","#mw-navigation","#p-search","/wiki/Nomenclature_of_monoclonal_antibodies","/wiki/File:Infliximab_structure2.jpg","//upload.wikimedia.org/wikipedia/commons/thumb/5/5c/Infliximab_structure2.jpg/220px-Infliximab_structure2.jpg","/wiki/Monoclonal_antibody#Applications","/wiki/File:Engineered_monoclonal_antibodies.svg","/wiki/Monoclonal_antibody#Production","/wiki/Chimeric_antibody","/wiki/Mouse","/wiki/Human","/wiki/Antigen","/wiki/Tumor_necrosis_factors","/wiki/Trade_name","/wiki/American_Society_of_Health-System_Pharmacists","/wiki/Drugs.com","http://www.drugs.com/monograph/infliximab.html","/wiki/Pregnancy_category","/wiki/Regulation_of_therapeutic_goods","/wiki/Prescription_drug","/wiki/United_States","/wiki/Route_of_administration","/wiki/Bioavailability","/wiki/Drug_metabolism","/wiki/Reticuloendothelial","/wiki/Biological_half-life","/wiki/CAS_registry_number","http://www.nlm.nih.gov/cgi/mesh/2009/MB_cgi?term=170277-31-3&rn=1","//upload.wikimedia.org/wikipedia/en/thumb/f/fb/Yes_check.svg/7px-Yes_check.svg.png","/wiki/Anatomical_Therapeutic_Chemical_Classification_System","/wiki/ATC_code_L04","http://www.whocc.no/atc_ddd_index/?code=L04AB02","/wiki/DrugBank","http://www.drugbank.ca/drugs/DB00065","/wiki/Unique_Ingredient_Identifier","http://fdasis.nlm.nih.gov/srs/srsdirect.jsp?regno=B72HH48FLU","//upload.wikimedia.org/wikipedia/en/thumb/f/fb/Yes_check.svg/7px-Yes_check.svg.png","/wiki/KEGG","http://www.kegg.jp/entry/D02598","//upload.wikimedia.org/wikipedia/en/thumb/f/fb/Yes_check.svg/7px-Yes_check.svg.png","/wiki/ChEMBL","https://www.ebi.ac.uk/chembldb/index.php/compound/inspect/CHEMBL1201581","//upload.wikimedia.org/wikipedia/commons/thumb/a/a2/X_mark.svg/7px-X_mark.svg.png","/wiki/Chemical_formula","/wiki/Carbon","/wiki/Hydrogen","/wiki/Nitrogen","/wiki/Oxygen","/wiki/Sulfur","/wiki/Molecular_mass","//upload.wikimedia.org/wikipedia/commons/thumb/a/a2/X_mark.svg/14px-X_mark.svg.png","/wiki/Wikipedia:WikiProject_Chemicals/Chembox_validation","//en.wikipedia.org/w/index.php?title=Special:ComparePages&rev1=458271995&page2=Infliximab","//upload.wikimedia.org/wikipedia/en/thumb/f/f2/Edit-clear.svg/40px-Edit-clear.svg.png","/wiki/Wikipedia:Cleanup","/wiki/Wikipedia:Manual_of_Style","/wiki/Template:Cleanup/doc","//en.wikipedia.org/w/index.php?title=Infliximab&action=edit","/wiki/International_Nonproprietary_Name","/wiki/Monoclonal_antibody","/wiki/TNF_alpha","/wiki/Autoimmune","/wiki/List_of_autoimmune_diseases","/wiki/Centocor","/wiki/Mitsubishi_Tanabe_Pharma","/w/index.php?title=Xian_Janssen&action=edit&redlink=1","/wiki/Schering-Plough","/wiki/Merck_%26_Co","#cite_note-JNJ_20071106_141812-1","/wiki/Biosimilar","/wiki/Hospira","#cite_note-george2013-2","/wiki/Food_and_Drug_Administration_(United_States)","/wiki/Psoriasis","/wiki/Crohn%27s_disease","/wiki/Ankylosing_spondylitis","/wiki/Psoriatic_arthritis","/wiki/Rheumatoid_arthritis","/wiki/Ulcerative_colitis","/wiki/Crohn%27s_disease","#cite_note-3","/wiki/Cytokine","/wiki/Receptor_(biochemistry)","/wiki/Antibody","/wiki/Monoclonal_antibody","/wiki/Jan_Vilcek","/wiki/New_York_University_School_of_Medicine","/wiki/Centocor","#cite_note-4","#cite_note-5","/wiki/Golimumab","/wiki/Adalimumab","/wiki/Certolizumab_pegol","/wiki/Etanercept","/wiki/CD120","/wiki/Fc_region","#cite_note-6","/wiki/Intravenous_therapy","/wiki/Route_of_administration","/wiki/Digestive_system","#cite_note-7","#Medical_uses","#Crohn.27s_disease","#Fistulizing_disease","#Inflammatory_disease","#Ulcerative_colitis","#Other","#Adverse_effects","#Pharmacology","#Availability.2Faffordability","#See_also","#References","#External_links","/w/index.php?title=Infliximab&action=edit&section=1","/w/index.php?title=Infliximab&action=edit&section=2","/wiki/Phenotype","/wiki/Crohn%27s_disease","/wiki/Fistula","/wiki/Inflammation","#cite_note-phenotypes-8","/w/index.php?title=Infliximab&action=edit&section=3","/wiki/Skin","/wiki/Bowel","#cite_note-Present-9","/wiki/Placebo","#cite_note-ACCENT2-10","/w/index.php?title=Infliximab&action=edit&section=4","/wiki/File:CD_colitis.jpg","//upload.wikimedia.org/wikipedia/commons/thumb/0/0e/CD_colitis.jpg/220px-CD_colitis.jpg","/wiki/File:CD_colitis.jpg","//bits.wikimedia.org/static-1.22wmf10/skins/common/images/magnify-clip.png","/wiki/Crohn%27s_disease","/wiki/Peptic_ulcer","/wiki/Colonoscopy","#cite_note-ACCENT1-11","/wiki/Prednisone","/wiki/Remission_(medicine)","#cite_note-topdown-12","/w/index.php?title=Infliximab&action=edit&section=5","/wiki/Tumour_necrosis_factor","/wiki/T_helper_cell#Th1.2FTh2_Model_for_helper_T_cells","/wiki/T_helper_cell#Th1.2FTh2_Model_for_helper_T_cells","#cite_note-ACT-13","/w/index.php?title=Infliximab&action=edit&section=6","/wiki/COPD","#cite_note-14","/wiki/Beh%C3%A7et%27s_disease","#cite_note-15","/wiki/Wikipedia:Manual_of_Style/Dates_and_numbers#Chronological_items","#cite_note-16","/wiki/Enthesitis","#cite_note-17","/w/index.php?title=Infliximab&action=edit&section=7","//upload.wikimedia.org/wikipedia/en/thumb/9/99/Question_book-new.svg/50px-Question_book-new.svg.png","//en.wikipedia.org/w/index.php?title=Infliximab&action=edit","/wiki/Help:Introduction_to_referencing/1","/wiki/Template:Citation_needed","/wiki/Wikipedia:Verifiability#Burden_of_evidence","/wiki/Remicade","/wiki/Enbrel","/wiki/Humira","/wiki/Immunosuppressants","/wiki/Blood_disorder","/wiki/Infection","/wiki/Lymphoma","/wiki/Hepatitis_B","/wiki/Tuberculosis","#cite_note-18","/wiki/Hepatosplenic_T-cell_lymphoma","/wiki/Lupus","/wiki/Demyelinating","/wiki/Central_nervous_system","/wiki/Psoriasis","/wiki/Vitiligo","/wiki/Leukopenia","/wiki/Neutropenia","/wiki/Thrombocytopenia","/wiki/Pancytopenia","#cite_note-19","#cite_note-20","#cite_note-21","/wiki/Methotrexate","#cite_note-22","#cite_note-ACCENT1-11","/wiki/Azathioprine","/wiki/Psoriasis","/wiki/Psoriatic_arthritis","/wiki/Ankylosing_spondylitis","/wiki/Rheumatoid_arthritis","/w/index.php?title=Infliximab&action=edit&section=8","/wiki/TNF_alpha","/wiki/Affinity_(pharmacology)","/wiki/T_cells","/wiki/Adalimumab","/wiki/Transmembrane","/wiki/Receptor_(immunology)","#cite_note-23","#cite_note-24","/wiki/Adalimumab","/wiki/Lysing","#cite_note-25","/wiki/Etanercept","/wiki/Specificity_(tests)","/wiki/Lymphotoxin","/wiki/Proinflammatory","/wiki/Cytokine","/wiki/Interleukin","/wiki/Leukocyte","/wiki/Endothelial","/wiki/Adhesion_molecule","/wiki/Transgenic","/w/index.php?title=Infliximab&action=edit&section=9","/wiki/Wikipedia:Citation_needed","#cite_note-26","#cite_note-JNJ_20071106_141812-1","#cite_note-JNJ_20071106_141812-1","#cite_note-27","/wiki/Crohn%27s_Disease_Activity_Index","#cite_note-28","/w/index.php?title=Infliximab&action=edit&section=10","/wiki/Biological_therapy_for_inflammatory_bowel_disease","/w/index.php?title=Infliximab&action=edit&section=11","#cite_ref-JNJ_20071106_141812_1-0","#cite_ref-JNJ_20071106_141812_1-1","#cite_ref-JNJ_20071106_141812_1-2","http://www.jnj.com/connect/NewsArchive/all-news-archive/20071106_141812","/wiki/Johnson_%26_Johnson","#cite_ref-george2013_2-0","http://www.bizjournals.com/philadelphia/news/2013/06/28/biliion-dollar-biotech-drug-may-soon.html","/wiki/Philadelphia_Business_Journal","#cite_ref-3","http://www.fda.gov/Drugs/DevelopmentApprovalProcess/HowDrugsareDevelopedandApproved/ApprovalApplications/TherapeuticBiologicApplications/ucm093327.htm","/wiki/Food_and_Drug_Administration_(United_States)","#cite_ref-4","/wiki/Digital_object_identifier","http://dx.doi.org/10.1016%2F0161-5890%2893%2990106-L","/wiki/PubMed_Identifier","//www.ncbi.nlm.nih.gov/pubmed/8232330","#cite_ref-5","http://www.sfgate.com/cgi-bin/article.cgi?f=/c/a/2007/05/08/BUGHAPMN021.DTL","/wiki/San_Francisco_Chronicle","#cite_ref-6","http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2119031","/wiki/Digital_object_identifier","http://dx.doi.org/10.1084%2Fjem.174.6.1483","/wiki/PubMed_Central","//www.ncbi.nlm.nih.gov/pmc/articles/PMC2119031","/wiki/PubMed_Identifier","//www.ncbi.nlm.nih.gov/pubmed/1660525","#cite_ref-7","/wiki/International_Standard_Book_Number","/wiki/Special:BookSources/3-7692-3483-9","#cite_ref-phenotypes_8-0","/wiki/Digital_object_identifier","http://dx.doi.org/10.1007%2Fs11938-003-0001-1","/wiki/PubMed_Identifier","//www.ncbi.nlm.nih.gov/pubmed/12744819","#cite_ref-Present_9-0","/wiki/Lloyd_Mayer","/wiki/The_New_England_Journal_of_Medicine","/wiki/Digital_object_identifier","http://dx.doi.org/10.1056%2FNEJM199905063401804","/wiki/PubMed_Identifier","//www.ncbi.nlm.nih.gov/pubmed/10228190","#cite_ref-ACCENT2_10-0","/wiki/The_New_England_Journal_of_Medicine","/wiki/Digital_object_identifier","http://dx.doi.org/10.1056%2FNEJMoa030815","/wiki/PubMed_Identifier","//www.ncbi.nlm.nih.gov/pubmed/14985485","#cite_ref-ACCENT1_11-0","#cite_ref-ACCENT1_11-1","/wiki/Digital_object_identifier","http://dx.doi.org/10.1016%2FS0140-6736%2802%2908512-4","/wiki/PubMed_Identifier","//www.ncbi.nlm.nih.gov/pubmed/12047962","#cite_ref-topdown_12-0","/wiki/Digital_object_identifier","http://dx.doi.org/10.1053%2Fbega.2003.0361","/wiki/PubMed_Identifier","//www.ncbi.nlm.nih.gov/pubmed/12617888","#cite_ref-ACT_13-0","/wiki/The_New_England_Journal_of_Medicine","/wiki/Digital_object_identifier","http://dx.doi.org/10.1056%2FNEJMoa050516","/wiki/PubMed_Identifier","//www.ncbi.nlm.nih.gov/pubmed/16339095","#cite_ref-14","/wiki/Digital_object_identifier","http://dx.doi.org/10.1164%2Frccm.200607-995OC","/wiki/PubMed_Identifier","//www.ncbi.nlm.nih.gov/pubmed/17290043","#cite_ref-15","http://ard.bmj.com/content/61/suppl_2/ii51.abstract","/wiki/Digital_object_identifier","/wiki/PubMed_Central","//www.ncbi.nlm.nih.gov/pmc/articles/PMC1766720","/wiki/PubMed_Identifier","//www.ncbi.nlm.nih.gov/pubmed/12379622","#cite_ref-16","/wiki/Digital_object_identifier","http://dx.doi.org/10.1007%2Fs10227-004-0115-7","/wiki/PubMed_Identifier","//www.ncbi.nlm.nih.gov/pubmed/15685387","#cite_ref-17","/wiki/PubMed_Identifier","//www.ncbi.nlm.nih.gov/pubmed/16724373","#cite_ref-18","http://www.nejm.org/doi/full/10.1056/NEJMoa011110#t=articleResults","/wiki/Digital_object_identifier","http://dx.doi.org/10.1056%2FNEJMoa011110","/wiki/PubMed_Identifier","//www.ncbi.nlm.nih.gov/pubmed/11596589","#cite_ref-19","http://www.remicade.com/remicade/global/hcp/healthcare_professionals.html","#cite_ref-20","http://www.fda.gov/medwatch/safety/2006/May_PIs/Remicade_PI.pdf","/wiki/Wikipedia:Link_rot","#cite_ref-21","http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalproducts/ucm175843.htm","/wiki/Food_and_Drug_Administration_(United_States)","#cite_ref-22","/wiki/PubMed_Identifier","//www.ncbi.nlm.nih.gov/pubmed/10622295","#cite_ref-23","/wiki/The_New_England_Journal_of_Medicine","/wiki/Digital_object_identifier","http://dx.doi.org/10.1056%2FNEJM200103223441207","/wiki/PubMed_Identifier","//www.ncbi.nlm.nih.gov/pubmed/11259725","#cite_ref-24","#cite_ref-25","#cite_ref-26","http://www.rxlist.com/remicade-drug.htm","#cite_ref-27","http://guidance.nice.org.uk/TA40/Guidance","#cite_ref-28","http://www.medicareaustralia.gov.au/provider/pbs/drugs1/crohns.jsp#N10041","/w/index.php?title=Infliximab&action=edit&section=12","http://www.remicade.com/","http://www.nras.org.uk/about_rheumatoid_arthritis/newly_diagnosed/which_drugs_are_used/antitnfa_treatment_in_rheumatoid_arthritis.aspx","http://www.druglib.com/druginfo/remicade/","http://www.remicade.com/remicade/global/hcp/hcp_pi.html","/wiki/Template:Immunosuppressants","/wiki/Template_talk:Immunosuppressants","//en.wikipedia.org/w/index.php?title=Template:Immunosuppressants&action=edit","/wiki/Immunomodulator","/wiki/Immunosuppressive_drug","/wiki/Immunosuppressant","/wiki/ATC_code_L04","/wiki/Antimetabolite","/wiki/Purine_synthesis_inhibitor","/wiki/Azathioprine","/wiki/Mycophenolic_acid","/wiki/Pyrimidine_synthesis_inhibitor","/wiki/Leflunomide","/wiki/Teriflunomide","/wiki/Antifolate","/wiki/Methotrexate","/wiki/Macrolide","/wiki/Interleukin_2","/wiki/FKBP","/wiki/Cyclophilin","/wiki/Calcineurin","/wiki/Tacrolimus","/wiki/Ciclosporin","/wiki/Pimecrolimus","/wiki/Abetimus","/wiki/Gusperimus","/wiki/Thalidomide","/wiki/Lenalidomide","/wiki/Interleukin_1_receptor_antagonist","/wiki/Anakinra","/wiki/Mammalian_target_of_rapamycin","/wiki/Sirolimus","/wiki/Everolimus","/wiki/Ridaforolimus","/wiki/Temsirolimus","/wiki/Umirolimus","/wiki/Zotarolimus","/wiki/Antibody","/wiki/Monoclonal_antibodies","/wiki/Complement_component_5","/wiki/Eculizumab","/wiki/TNF_inhibitor","/wiki/Adalimumab","/wiki/Afelimomab","/wiki/Certolizumab_pegol","/wiki/Golimumab","/wiki/Nerelimomab","/wiki/Interleukin_5","/wiki/Mepolizumab","/wiki/Immunoglobulin_E","/wiki/Omalizumab","/wiki/Interferon","/wiki/Faralimomab","/wiki/Interleukin_6","/wiki/Elsilimomab","/wiki/Interleukin_12","/wiki/Interleukin_23","/wiki/Lebrikizumab","/wiki/Ustekinumab","/wiki/CD3_(immunology)","/wiki/Muromonab-CD3","/wiki/Otelixizumab","/wiki/Teplizumab","/wiki/Visilizumab","/wiki/CD4","/wiki/Clenoliximab","/wiki/Keliximab","/wiki/Zanolimumab","/wiki/CD11a","/wiki/Efalizumab","/wiki/CD18","/wiki/Erlizumab","/wiki/CD20","/wiki/Afutuzumab","/wiki/Rituximab","/wiki/Ocrelizumab","/wiki/Pascolizumab","/wiki/CD23","/wiki/Gomiliximab","/wiki/Lumiliximab","/wiki/CD40_(protein)","/wiki/Teneliximab","/wiki/Toralizumab","/wiki/L-selectin","/wiki/Aselizumab","/wiki/CD80","/wiki/Galiximab","/wiki/Basigin","/wiki/Gavilimomab","/wiki/CD154","/wiki/Ruplizumab","/wiki/Belimumab","/wiki/CTLA-4","/wiki/Ipilimumab","/wiki/Tremelimumab","/wiki/Chloramphenicol_acetyltransferase","/wiki/Bertilimumab","/wiki/Lerdelimumab","/wiki/Metelimumab","/wiki/Integrin","/wiki/Natalizumab","/wiki/Interleukin-6_receptor","/wiki/Tocilizumab","/wiki/Lymphocyte_function-associated_antigen_1","/wiki/Odulimomab","/wiki/IL-2_receptor","/wiki/Basiliximab","/wiki/Daclizumab","/wiki/Inolimomab","/wiki/T_cell","/wiki/Zolimomab_aritox","/wiki/Atorolimumab","/wiki/Cedelizumab","/wiki/Fontolizumab","/wiki/Maslimomab","/wiki/Morolimumab","/wiki/Pexelizumab","/wiki/Reslizumab","/wiki/Rovelizumab","/wiki/Siplizumab","/wiki/Talizumab","/wiki/Telimomab_aritox","/wiki/Vapaliximab","/wiki/Vepalimomab","/wiki/Polyclonal_antibodies","/wiki/Anti-thymocyte_globulin","/wiki/Anti-lymphocyte_globulin","/wiki/Fusion_protein","/wiki/CTLA-4","/wiki/Abatacept","/wiki/Belatacept","/wiki/TNF_inhibitor","/wiki/Etanercept","/wiki/Pegsunercept","/wiki/Aflibercept","/wiki/Alefacept","/wiki/Rilonacept","/wiki/Template:Medicine_navs","/wiki/Lymphocyte","/wiki/Template:Lymphocytes","/wiki/Template:Lymphocytic_immune_system","/wiki/Template:Autoantigens","/wiki/Template:Autoantibodies","/wiki/Template:Complement_system","/wiki/Template:Immunoglobulin_superfamily_immune_receptors","/wiki/Template:Lymphoid_and_complement_immunodeficiency","/wiki/Template:Immunoproliferative_immunoglobulin_disorders","/wiki/Template:Hypersensitivity_and_autoimmune_diseases","/wiki/Template:Lymphoid_malignancy","/wiki/Template:Immunologic_techniques_and_tests","/wiki/Template:Immunostimulants","/wiki/Template:Immunosuppressants","/wiki/Template:Monoclonals_for_immune_system","/wiki/Template_talk:Monoclonals_for_immune_system","//en.wikipedia.org/w/index.php?title=Template:Monoclonals_for_immune_system&action=edit","/wiki/Monoclonal_antibodies","/wiki/Immune_system","/wiki/Immune_system","/wiki/Immunosuppression","/wiki/Adalimumab","/wiki/Anifrolumab","/wiki/Atorolimumab","/wiki/Belimumab","/wiki/Brodalumab","/wiki/Carlumab","/wiki/Dupilumab","/wiki/Eldelumab","/wiki/Fresolimumab","/wiki/Golimumab","/wiki/Lerdelimumab","/wiki/Lirilumab","/wiki/Mavrilimumab","/wiki/Metelimumab","/wiki/Morolimumab","/wiki/Namilumab","/wiki/Oxelumab","/wiki/Placulumab","/wiki/Sarilumab","/wiki/Sifalimumab","/wiki/Tabalumab","/wiki/Ipilimumab","/wiki/Tremelimumab","/wiki/Nivolumab","/wiki/Urelumab","/wiki/Bertilimumab","/wiki/Zanolimumab","/wiki/Afelimomab","/wiki/Elsilimomab","/wiki/Faralimomab","/wiki/Gavilimomab","/wiki/Inolimomab","/wiki/Maslimomab","/wiki/Nerelimomab","/wiki/Odulimomab","/wiki/Telimomab_aritox","/wiki/Vepalimomab","/wiki/Zolimomab_aritox","/wiki/Chimeric_antibody","/wiki/Basiliximab","/wiki/Clenoliximab","/wiki/Galiximab","/wiki/Gomiliximab","/wiki/Keliximab","/wiki/Lumiliximab","/wiki/Priliximab","/wiki/Teneliximab","/wiki/Vapaliximab","/wiki/Humanized_antibody","/wiki/Aselizumab","/wiki/Apolizumab","/wiki/Benralizumab","/wiki/Cedelizumab","/wiki/Certolizumab_pegol","/wiki/Daclizumab","/wiki/Eculizumab","/wiki/Efalizumab","/wiki/Epratuzumab","/wiki/Erlizumab","/wiki/Etrolizumab","/wiki/Fontolizumab","/wiki/Itolizumab","/wiki/Lambrolizumab","/wiki/Lampalizumab","/wiki/Ligelizumab","/wiki/Mepolizumab","/wiki/Mogamulizumab","/wiki/Natalizumab","/wiki/Ocrelizumab","/wiki/Omalizumab","/wiki/Ozoralizumab","/wiki/Pascolizumab","/wiki/Pateclizumab","/wiki/Pexelizumab","/wiki/Pidilizumab","/wiki/PRO_140","/wiki/Reslizumab","/wiki/Rontalizumab","/wiki/Rovelizumab","/wiki/Ruplizumab","/wiki/Quilizumab","/wiki/Samalizumab","/wiki/Siplizumab","/wiki/Talizumab","/wiki/Teplizumab","/wiki/Tocilizumab","/wiki/Toralizumab","/wiki/Tregalizumab","/wiki/Vatelizumab","/wiki/Vedolizumab","/wiki/Visilizumab","/wiki/TGN1412","/wiki/Ibalizumab","/wiki/Otelixizumab","/wiki/Interleukin","/wiki/Briakinumab","/wiki/Canakinumab","/wiki/Fezakinumab","/wiki/Guselkumab","/wiki/Secukinumab","/wiki/Sirukumab","/wiki/Tralokinumab","/wiki/Ustekinumab","/wiki/Anrukinzumab","/wiki/Clazakizumab","/wiki/Enokizumab","/wiki/Gevokizumab","/wiki/Ixekizumab","/wiki/Lebrikizumab","/wiki/Olokizumab","/wiki/Perakizumab","/wiki/Tildrakizumab","/wiki/Lesion","/wiki/Besilesomab","/wiki/Technetium_(99mTc)_fanolesomab","/wiki/Lemalesomab","/wiki/Technetium_(99mTc)_sulesomab","/wiki/List_of_World_Health_Organization_Essential_Medicines","/wiki/List_of_withdrawn_drugs","/wiki/Clinical_trial","/wiki/Clinical_trial#Phase_III","/wiki/Clinical_trial#Phase_II","/wiki/Template:Medicine_navs","/wiki/Lymphocyte","/wiki/Template:Lymphocytes","/wiki/Template:Lymphocytic_immune_system","/wiki/Template:Autoantigens","/wiki/Template:Autoantibodies","/wiki/Template:Complement_system","/wiki/Template:Immunoglobulin_superfamily_immune_receptors","/wiki/Template:Lymphoid_and_complement_immunodeficiency","/wiki/Template:Immunoproliferative_immunoglobulin_disorders","/wiki/Template:Hypersensitivity_and_autoimmune_diseases","/wiki/Template:Lymphoid_malignancy","/wiki/Template:Immunologic_techniques_and_tests","/wiki/Template:Immunostimulants","/wiki/Template:Immunosuppressants","//en.wikipedia.org/w/index.php?title=Special:CentralAutoLogin/start&type=1x1&from=enwiki","http://en.wikipedia.org/w/index.php?title=Infliximab&oldid=563845990","/wiki/Help:Categories","/wiki/Category:Centocor","/wiki/Category:TNF_inhibitors","/wiki/Category:Monoclonal_antibodies","/wiki/Category:Engineered_proteins","/wiki/Category:Schering-Plough","/wiki/Category:Immunosuppressants","/wiki/Category:Pages_with_DOIs_inactive_since_2012","/wiki/Category:All_articles_with_dead_external_links","/wiki/Category:Articles_with_dead_external_links_from_November_2009","/wiki/Category:Chemical_compounds_which_do_not_have_a_ChemSpiderID","/wiki/Category:Articles_with_changed_EBI_identifier","/wiki/Category:Drugboxes_which_contain_changes_to_verified_fields","/wiki/Category:Articles_needing_cleanup_from_January_2010","/wiki/Category:All_articles_needing_cleanup","/wiki/Category:Cleanup_tagged_articles_without_a_reason_field_from_January_2010","/wiki/Category:Wikipedia_pages_needing_cleanup_from_January_2010","/wiki/Category:Vague_or_ambiguous_time_from_April_2010","/wiki/Category:Articles_needing_additional_references_from_November_2009","/wiki/Category:All_articles_needing_additional_references","/wiki/Category:All_articles_with_unsourced_statements","/wiki/Category:Articles_with_unsourced_statements_from_March_2009","/w/index.php?title=Special:UserLogin&returnto=Infliximab&type=signup","/w/index.php?title=Special:UserLogin&returnto=Infliximab","/wiki/Infliximab","/wiki/Talk:Infliximab","#","/wiki/Infliximab","/w/index.php?title=Infliximab&action=edit","/w/index.php?title=Infliximab&action=history","#","/w/index.php","//bits.wikimedia.org/static-1.22wmf10/skins/vector/images/search-ltr.png?303-4","/wiki/Main_Page","/wiki/Main_Page","/wiki/Portal:Contents","/wiki/Portal:Featured_content","/wiki/Portal:Current_events","/wiki/Special:Random","//donate.wikimedia.org/wiki/Special:FundraiserRedirector?utm_source=donate&utm_medium=sidebar&utm_campaign=C13_en.wikipedia.org&uselang=en","/wiki/Help:Contents","/wiki/Wikipedia:About","/wiki/Wikipedia:Community_portal","/wiki/Special:RecentChanges","//en.wikipedia.org/wiki/Wikipedia:Contact_us","/wiki/Special:WhatLinksHere/Infliximab","/wiki/Special:RecentChangesLinked/Infliximab","/wiki/Wikipedia:File_Upload_Wizard","/wiki/Special:SpecialPages","/w/index.php?title=Infliximab&oldid=563845990","/w/index.php?title=Infliximab&action=info","//www.wikidata.org/wiki/Q415264","/w/index.php?title=Special:Cite&page=Infliximab&id=563845990","/w/index.php?title=Special:Book&bookcmd=book_creator&referer=Infliximab","/w/index.php?title=Special:Book&bookcmd=render_article&arttitle=Infliximab&oldid=563845990&writer=rl","/w/index.php?title=Infliximab&printable=yes","//ar.wikipedia.org/wiki/%D8%A5%D9%86%D9%81%D9%84%D9%8A%D9%83%D8%B3%D9%8A%D9%85%D8%A7%D8%A8","//de.wikipedia.org/wiki/Infliximab","//es.wikipedia.org/wiki/Infliximab","//fr.wikipedia.org/wiki/Infliximab","//it.wikipedia.org/wiki/Infliximab","//he.wikipedia.org/wiki/%D7%A8%D7%9E%D7%99%D7%A7%D7%99%D7%99%D7%93","//nl.wikipedia.org/wiki/Infliximab","//ja.wikipedia.org/wiki/%E3%82%A4%E3%83%B3%E3%83%95%E3%83%AA%E3%82%AD%E3%82%B7%E3%83%9E%E3%83%96","//pl.wikipedia.org/wiki/Infliksymab","//pt.wikipedia.org/wiki/Infliximabe","//ru.wikipedia.org/wiki/%D0%98%D0%BD%D1%84%D0%BB%D0%B8%D0%BA%D1%81%D0%B8%D0%BC%D0%B0%D0%B1","//fi.wikipedia.org/wiki/Infliksimabi","//sv.wikipedia.org/wiki/Infliximab","#","//www.wikidata.org/wiki/Q415264#sitelinks-wikipedia","//en.wikipedia.org/wiki/Wikipedia:Text_of_Creative_Commons_Attribution-ShareAlike_3.0_Unported_License","//creativecommons.org/licenses/by-sa/3.0/","//wikimediafoundation.org/wiki/Terms_of_Use","//wikimediafoundation.org/wiki/Privacy_policy","//www.wikimediafoundation.org/","//wikimediafoundation.org/wiki/Privacy_policy","/wiki/Wikipedia:About","/wiki/Wikipedia:General_disclaimer","//en.wikipedia.org/wiki/Wikipedia:Contact_us","//en.m.wikipedia.org/wiki/Infliximab","//wikimediafoundation.org/","//bits.wikimedia.org/images/wikimedia-button.png","//www.mediawiki.org/","//bits.wikimedia.org/static-1.22wmf10/skins/common/images/poweredby_mediawiki_88x31.png","//bits.wikimedia.org/en.wikipedia.org/load.php?debug=false&lang=en&modules=site&only=scripts&skin=vector&*"],"instances":["immunology","medicine","united_states","tests","pharmacology"],"pdf":["http://www.fda.gov/medwatch/safety/2006/May_PIs/Remicade_PI.pdf"],"categories":["Centocor","TNF inhibitors","Monoclonal antibodies","Engineered proteins","Schering-Plough","Immunosuppressants"],"headings":["Medical uses","Adverse effects","Pharmacology","Availability/affordability","See also","References","External links"],"image":["//upload.wikimedia.org/wikipedia/commons/thumb/5/5c/Infliximab_structure2.jpg/220px-Infliximab_structure2.jpg","//upload.wikimedia.org/wikipedia/en/thumb/f/fb/Yes_check.svg/7px-Yes_check.svg.png","//upload.wikimedia.org/wikipedia/en/thumb/f/fb/Yes_check.svg/7px-Yes_check.svg.png","//upload.wikimedia.org/wikipedia/en/thumb/f/fb/Yes_check.svg/7px-Yes_check.svg.png","//upload.wikimedia.org/wikipedia/commons/thumb/a/a2/X_mark.svg/7px-X_mark.svg.png","//upload.wikimedia.org/wikipedia/commons/thumb/a/a2/X_mark.svg/14px-X_mark.svg.png","//upload.wikimedia.org/wikipedia/en/thumb/f/f2/Edit-clear.svg/40px-Edit-clear.svg.png","//upload.wikimedia.org/wikipedia/commons/thumb/0/0e/CD_colitis.jpg/220px-CD_colitis.jpg","//bits.wikimedia.org/static-1.22wmf10/skins/common/images/magnify-clip.png","//upload.wikimedia.org/wikipedia/en/thumb/9/99/Question_book-new.svg/50px-Question_book-new.svg.png","//en.wikipedia.org/w/index.php?title=Special:CentralAutoLogin/start&type=1x1&from=enwiki","//bits.wikimedia.org/static-1.22wmf10/skins/vector/images/search-ltr.png?303-4","//bits.wikimedia.org/images/wikimedia-button.png","//bits.wikimedia.org/static-1.22wmf10/skins/common/images/poweredby_mediawiki_88x31.png"],"tags":[["food_and_drug_administration","united_states"],["food_and_drug_administration","united_states"],["receptor","biochemistry"],["remission","medicine"],["food_and_drug_administration","united_states"],["affinity","pharmacology"],["receptor","immunology"],["specificity","tests"]],"members":["receptor","remission","food_and_drug_administration","specificity","affinity"],"related":["Tumor_necrosis_factors","Reticuloendothelial","International_Nonproprietary_Name","Monoclonal_antibody","TNF_alpha","Autoimmune","List_of_autoimmune_diseases","Centocor","Mitsubishi_Tanabe_Pharma","Xian_Janssen","Schering-Plough","Merck_&_Co","Johnson_&_Johnson","Biosimilar","Hospira","Philadelphia_Business_Journal","Food_and_Drug_Administration_(United_States)","Psoriasis","Crohn's_disease","Ankylosing_spondylitis","Psoriatic_arthritis","Rheumatoid_arthritis","Ulcerative_colitis","Crohn's_disease","Food_and_Drug_Administration_(United_States)","Cytokine","Receptor_(biochemistry)","Antibody","Monoclonal_antibody","Jan_Vilcek","New_York_University_School_of_Medicine","Centocor","Golimumab","Adalimumab","Certolizumab_pegol","Etanercept","CD120","Fc_region","Intravenous_therapy","Route_of_administration","Digestive_system","Phenotype","Crohn's_disease","Fistula","Inflammation","Skin","Bowel","Placebo","Peptic_ulcer","Colonoscopy","Prednisone","Remission_(medicine)","Tumour_necrosis_factor","COPD","Behçet's_disease","Enthesitis","Remicade","Enbrel","Humira","Immunosuppressants","Blood_disorder","Infection","Lymphoma","Hepatitis_B","Tuberculosis","Hepatosplenic_T-cell_lymphoma","Lupus","Demyelinating","Central_nervous_system","Psoriasis","Vitiligo","Leukopenia","Neutropenia","Thrombocytopenia","Pancytopenia","Food_and_Drug_Administration_(United_States)","Methotrexate","Azathioprine","Psoriasis","Psoriatic_arthritis","Ankylosing_spondylitis","Rheumatoid_arthritis","TNF_alpha","Affinity_(pharmacology)","T_cells","Adalimumab","Transmembrane","Receptor_(immunology)","The_New_England_Journal_of_Medicine","Adalimumab","Lysing","Etanercept","Specificity_(tests)","Lymphotoxin","Proinflammatory","Cytokine","Interleukin","Leukocyte","Endothelial","Adhesion_molecule","Transgenic","Crohn's_Disease_Activity_Index","Biological_therapy_for_inflammatory_bowel_disease"]}